Amendment Under 37 C.F.R. § 1.116 Attorney Docket No.: Q64360

U.S. Appln. No.: 09/856,374

## **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application:

## LISTING OF CLAIMS:

**1-12.** (canceled)

- 13. (currently amended): A therapeutic or preventive method for cerebrovascular disorders comprising introducing an HGF gene and/or a VEGF gene in the form of HJVHVJ-liposomes by direct injection into the subarachnoid space in humans thereby treating or preventing said cerebrovascular disorders.
- 14. (currently amended): A therapeutic or preventive method for reduced blood flow comprising introducing an HGF gene and/or a VEGF gene in the form of HJVHVJ-liposomes by direct injection into the subarachnoid space in humans thereby treating or preventing said reduced blood flow.
- 15. (currently amended): A method of promoting cerebral angiogenesis comprising introducing an HGF gene and/or VEGF gene in the form of HJVHVJ-liposomes by direct injection into the subarachnoid space in humans thereby promoting said cerebral angiogenesis.
- 16. (currently amended): A method of suppressing neuronal death in the brain comprising introducing an HGF gene in the form of <u>HJVHVJ</u>-liposomes by direct injection into the subarachnoid space in humans thereby suppressing said neuronal death in the brain.

2

Amendment Under 37 C.F.R. § 1.116

U.S. Appln. No.: 09/856,374

Attorney Docket No.: Q64360

17. (currently amended): A method of suppressing apoptosis of nerve cells in the brain comprising introducing by direct injection an HGF gene in the form of HJVHVJ-liposomes into the subarachnoid space in humans thereby suppressing said apoptosis of nerve cells.

18-25. (canceled)